Zimmer Biomet (NYSE:ZBH) had its price target cut by Morgan Stanley from $150.00 to $148.00 in a research note published on Monday. They currently have an overweight rating on the medical equipment provider’s stock.
A number of other brokerages have also commented on ZBH. Jefferies Group reiterated a buy rating and issued a $136.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. SunTrust Banks upped their price target on shares of Zimmer Biomet to $142.00 and gave the company a buy rating in a research note on Monday, January 29th. Stifel Nicolaus reiterated a hold rating and issued a $120.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. TheStreet lowered shares of Zimmer Biomet from a b- rating to a c+ rating in a research note on Friday, November 24th. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Zimmer Biomet in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet has an average rating of Buy and an average price target of $141.56.
Zimmer Biomet (NYSE ZBH) opened at $119.88 on Monday. The firm has a market cap of $24,270.00, a PE ratio of 45.58, a PEG ratio of 2.09 and a beta of 1.08. Zimmer Biomet has a 52 week low of $108.03 and a 52 week high of $133.49. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.83 and a current ratio of 1.52.
The business also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s payout ratio is 36.50%.
In related news, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $115.95, for a total value of $2,414,774.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bryan C. Hanson acquired 25,077 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was bought at an average cost of $119.68 per share, with a total value of $3,001,215.36. The disclosure for this purchase can be found here. 1.07% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Bank of Nova Scotia Trust Co. bought a new position in Zimmer Biomet in the 3rd quarter valued at approximately $112,000. FNY Managed Accounts LLC bought a new position in Zimmer Biomet in the 3rd quarter valued at approximately $117,000. Cerebellum GP LLC bought a new position in Zimmer Biomet in the 4th quarter valued at approximately $133,000. We Are One Seven LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at approximately $137,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in Zimmer Biomet in the 3rd quarter valued at approximately $140,000. 88.18% of the stock is owned by institutional investors and hedge funds.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.